Ali Hiba Qassem, Mahdi Nadham Kadham, Al-Jowher Mohammad Husein
Department of Microbiology, College of Medicine, University of Basrah, Iraq.
Department of Surgery, College of Medicine, University of Basrah, Iraq.
J Pak Med Assoc. 2013 Sep;63(9):1138-41.
To evaluate the role of cancer antigen CA15-3 in the diagnosis, prognosis, followup and treatment of breast cancer.
The case-control study was done from October 2009 to February 2011 at the Al-Basrah Hospital in Basrah, Iraq. Blood samples were collected from 30 women with primary breast cancer before the invasive procedure. Another set of blood samples were collected from 23 of the cases after three cycles of chemotherapy. Besides, 20 serum samples were collected from apparently healthy women as a control group from the outpatient department. Enzyme-linked immunosorbent assay (ELISA) test was used for detection of serum CA15-3.
Mean CA15-3 level for the cases (79.15 +/- 27.54 U/ml) was significantly higher than the controls (24.34 +/- 11.68 U/ml) (p < 0.05), with 93.3% sensitivity and 96.6% specificity. There was a significant positive correlation with the disease stage and tumour size ( p < 0.05). After three cycles of chemotherapy, the CA15-3 level significantly decreased ( p < 0.05). Cases who developed recurrence were found to have a significantly higher CA15-3 level than those who did not ( p < 0.05).
CA15-3 is an important diagnostic, prognostic indicator and good predictor for relapse.
评估癌抗原CA15 - 3在乳腺癌诊断、预后、随访及治疗中的作用。
2009年10月至2011年2月在伊拉克巴士拉的巴士拉医院进行病例对照研究。在侵入性操作前，从30例原发性乳腺癌女性患者中采集血样。另外，在三个化疗周期后，从其中23例患者中采集另一组血样。此外，从门诊部明显健康的女性中采集20份血清样本作为对照组。采用酶联免疫吸附测定（ELISA）法检测血清CA15 - 3。
病例组的平均CA15 - 3水平（79.15±27.54 U/ml）显著高于对照组（24.34±11.68 U/ml）（p < 0.05），敏感性为93.3%，特异性为96.6%。与疾病分期和肿瘤大小呈显著正相关（p < 0.05）。三个化疗周期后，CA15 - 3水平显著下降（p < 0.05）。发现复发患者的CA15 - 3水平显著高于未复发患者（p < 0.05）。
CA15 - 3是一种重要的诊断、预后指标及复发的良好预测指标。
